Recent Finacing
Recent Raise
Therachon develops TA-46, a soluble FGFR3 decoy protein therapy for achondroplasia, running a Phase 1 dose-escalation trial and a multi-country natural-history study in children.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Therachon.
